Aker BioMarine Antarctic AS reported a 5% year-over-year increase in revenue for the second quarter of 2026, according to results released on July 10, 2026. The Norwegian krill harvesting company credited strengthened demand for its krill oil products across key markets for the growth. The quarter underscores the continued expansion of the omega-3 supplement sector. Reported revenue reached NOK 897 million, up from NOK 854 million in the same period last year.
Context — why this matters now
The global omega-3 market is projected to grow at a compound annual growth rate of 7.5% from 2025 to 2030, reaching an estimated value of $4.8 billion. Aker BioMarine’s performance aligns with this trajectory, contrasting with a more volatile period in 2024 when supply chain disruptions impacted quarterly results. The company's last significant revenue jump was a 7% increase in Q4 2025, signaling a return to steady growth.
Consumer interest in marine-based supplements for heart and joint health continues to outpace plant-based alternatives. The current macro backdrop of stable energy prices has provided manageable operational costs for harvesting vessels. The trigger for this quarter's growth appears linked to successful marketing initiatives and expanded distribution channels in the Asia-Pacific region.
Krill oil, rich in phospholipid-bound omega-3s, is gaining market share against traditional fish oil. Its superior bioavailability is a key differentiator driving consumer preference. The sector benefits from an aging demographic in developed markets increasingly focused on preventative healthcare.
Data — what the numbers show
Aker BioMarine's Q2 2026 revenue reached NOK 897 million. This compares to revenue of NOK 854 million in Q2 2025. The company's harvest volume for the quarter was 18,550 tonnes of krill. This represents an increase from the 17,900 tonnes harvested in the prior-year quarter.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|
| Revenue (NOK millions) | 897 | 854 | +5.0% |
| Harvest Volume (tonnes) | 18,550 | 17,900 | +3.6% |
The average selling price per tonne of krill oil equivalents saw a modest increase. This indicates stable pricing power despite inflationary pressures. For context, the VanEck Vectors Agribusiness ETF (MOO) is up 4% year-to-date, slightly underperforming Aker's revenue growth. The company's performance highlights the niche strength of specialized commodities.
Analysis — what it means for markets / sectors / tickers
The positive results from Aker BioMarine are a bullish signal for the broader nutritional ingredients sector. Companies like BASF SE (BAS.DE), a major producer of omega-3s, and Royal DSM (DSM.AS) could see correlated investor interest. The krill oil supply chain, including enzyme manufacturers like Novozymes (NZYM-B.CO), may also experience secondary benefits from sustained demand.
A key risk to this outlook is the concentration of krill harvesting in the ecologically sensitive Antarctic region. Regulatory changes from the Commission for the Conservation of Antarctic Marine Living Resources could impose stricter catch limits. This represents a potential constraint on long-term volume growth that investors must monitor.
Institutional positioning in the sustainable nutrition space has increased over the past year. Flow data suggests long-term capital is accumulating in companies with transparent supply chains and certified sustainable practices. Aker BioMarine’s Marine Stewardship Council certification aligns with this trend, making it a potential beneficiary.
Outlook — what to watch next
The next major catalyst for Aker BioMarine is the Q3 2026 earnings report, expected in mid-October. This period will test the sustainability of the Q2 growth momentum. Investors should monitor the company's quarterly harvest volumes against its total allowable catch of 45,000 tonnes for the 2025/2026 season.
Key levels to watch include the company's EBITDA margin, which will be scrutinized for any cost inflation pressures. The USD/NOK exchange rate is another critical variable, as sales are predominantly in US dollars while costs are in Norwegian kroner. A strengthening krone could pressure profitability.
The FAO Fish Price Index, scheduled for update in late August, will provide a broader context for global marine commodity trends. Any significant deviation in this index could signal changing demand dynamics that may affect Aker's pricing power in subsequent quarters.
Frequently Asked Questions
What is Aker BioMarine's main business?
Aker BioMarine is a Norwegian biotechnology company that harvests krill from Antarctic waters. Its primary products include krill oil for human dietary supplements, which is rich in Omega-3 phospholipids, and ingredients for aquaculture feed. The company operates a fully transparent value chain from harvesting to manufacturing.
How does krill oil differ from regular fish oil?
Krill oil contains omega-3 fatty acids bound to phospholipids, which may enhance absorption in the human body compared to the triglyceride form found in most fish oils. Krill oil also naturally contains the antioxidant astaxanthin, which helps prevent oxidation. This biochemical difference is a primary driver of its premium pricing and market growth.
Is krill harvesting environmentally sustainable?
Aker BioMarine's krill fishery is certified by the Marine Stewardship Council (MSC) for sustainable practices. The company participates in scientific research and adheres to strict catch limits set by the international Commission for the Conservation of Antarctic Marine Living Resources. However, some environmental groups continue to advocate for stricter regulations due to the Antarctic ecosystem's fragility.
Bottom Line
Aker BioMarine's revenue growth confirms strong demand for premium, sustainable omega-3 ingredients.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
